Brainomix Secures £18.8m Series C to Accelerate U.S. Expansion of AI Stroke and Lung Platforms

New updates have been reported about Brainomix.

Brainomix has expanded its Series C round with an additional £4.8 million, bringing total proceeds to £18.8 million (about $25.4 million) to fund growth of its AI imaging platforms for stroke and lung fibrosis. The extension, led by existing backers Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund and joined by new U.S. investor Modi Ventures, is aimed primarily at scaling U.S. deployment of Brainomix 360 Stroke and e-Lung across hospitals.

With an established U.S. footprint and multiple FDA-cleared AI solutions, Brainomix plans to invest the new capital in faster rollout, deeper customer support, and smoother integration of its technology into clinical workflows in the U.S. and Europe. CEO and co-founder Dr. Michalis Papadakis said the funding underlines investor confidence in the company’s platform and its role in speeding stroke care and enabling earlier, more consistent decisions in lung fibrosis.

The Brainomix 360 Stroke platform is designed to automate imaging assessment across the acute stroke pathway, supporting treatment and transfer decisions regardless of local expertise, while the e-Lung technology uses CT-based biomarkers to detect, monitor, and predict progression of fibrosing lung disease. Investor Modi Ventures highlighted clinical data showing that Brainomix 360 Stroke can increase rates of endovascular thrombectomy and reduce triage and transfer delays, particularly in primary stroke centers.

Strategically, the round strengthens Brainomix’s capital position to drive market penetration in more than 20 countries where it already operates and to deepen its presence in the key U.S. market. For stakeholders, the financing signals continued institutional support for Brainomix’s AI-first imaging model, potentially positioning the company for further commercial scale-up, broader adoption among health systems, and a stronger foundation for future partnerships or exit options.